Chronic infections such as human immunodeficiency virus (HIV) and tuberculosis (TB) are globally dominant diseases where treatment is often costly with limited availability and increasing antimicrobial resistance. New therapeutic strategies are therefore desirable, but to develop new treatment options a good biological understanding of the disease mechanisms is needed.
The research group focuses on studies of immune mechanisms involved in HIV and TB. The immune responses against chronic infections work through a balance between stimulating and inhibitory mechanisms to partly protect the host by defeating the microbe while preventing a harmful overreaction of the immune system. The regulation of this balance varies between patients and disease stages. Immunological biomarkers can provide information about this regulation, the risk and progression of disease as well as efficacy of treatment. Candidate biomarkers, regulatory mechanisms and potential immunotherapies, however, must be studied both in biological material from patients (biobank) and in clinical trials before it can be concluded whether they can be used in clinical practice.
FOCUS OF RESEARCH
Through translational research and in collaboration with strong national and international basic research groups and in various consortiums we aim to increase the knowledge about immune pathogenesis in infections, explore diagnostic, prognostic and treatment efficacy biomarkers as well as test new therapies in clinical trials by recruiting patients from the Dep. of Infectious Diseases, Oslo University Hospital (OUH).
- Preclinical studies using human biobank material collected from the department's patients.
- Clinical phase I/II intervention trials of new host-directed therapies.
- Clinical research of HIV, TB and viral hepatitis through the department's Quality Registries.
- Self-initiated projects in collaboration with national and international partners and supported research in collaboration with industry.
- Clinical partner in joint multidisciplinary studies of influenza, antimicrobial resistance, sepsis and various inflammatory conditions.
- Facilitate combinations of post-doctoral positions with clinical work at the Dep. of Infectious Diseases, Oslo University Hospital.
Early phase drug development: From idea to concept
Feb 3, 2017
Feb 2, 2017
Oncolytic peptide LTX-315; the road from basic science to clinical trials
Jan 26, 2017
Chronic Infections group
[No title available]
Tidsskr Nor Laegeforen, 137 (3), 205-207